Canaccord Genuity Reiterates Rating on Tango Therapeutics, Inc. $TNGX
Key Points
- Canaccord Genuity now rates Tango Therapeutics, Inc. ($TNGX) "buy" with a $42 target.
- Canaccord Genuity's $42 price target implies 27.66% upside from Tango Therapeutics, Inc.'s ($TNGX) current $32.90 share price.
- The Street's average $TNGX price target is $44.75 (Strong Buy).
- $TNGX last traded around $32.90.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Canaccord Genuity reiterated its rating on Tango Therapeutics, Inc. ($TNGX) to a "buy" rating in a recent research note and set a price target of $42, a 27.66% upside from the current price.
Tango Therapeutics, Inc. Stock Up 41.0%
Shares of Tango Therapeutics, Inc. ($TNGX) traded around $32.90 on Saturday, up 41.0% for the day.
Tango Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Get Tango Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TNGX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.